Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway

Cancer Letters

Volumn 329, Issue 1, 2013, Pages 9-16

  Gopalan, Archana ^a   Yu, Weiping ^b   Sanders, Bob G ^b   Kline, Kimberly ^a  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Apoptosis; C Jun N terminal kinase (JNK); CCAAT enhancer binding protein homologous protein (CHOP); Death receptor 5 (DR5); Human breast cancer cells; Simvastatin (SVA)

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; BIOLOGICAL MARKER; CASPASE 8; CASPASE 9; CCAAT ENHANCER BINDING PROTEIN HOMOLOGOUS PROTEIN; DEATH RECEPTOR 5; GERANYLGERANYL PYROPHOSPHATE; MEVALONIC ACID; SIMVASTATIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MEVALONIC ACID; POLYISOPRENYL PHOSPHATES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; SESQUITERPENES; SIGNAL TRANSDUCTION; SIMVASTATIN; TRANSCRIPTION FACTOR CHOP;

EID: 84871722764     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.031     Document Type: Article

References (42)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62:0-29.
2. Moreno-Aspitia A., Perez E.A. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin. Ther. 2009, 31:1619-1640.
3. No M., Choi E.J., Kim I.A. Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol. Ther. 2009, 8:2351-2361.
4. Nahta R., Esteva F.J. HER2 therapy: molecular mechanisms of tratuzumab resistance. Breast Cancer Res. 2006, 8:215.
5. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
6. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Ann. Rev. Biochem. 1996, 65:241-269.
7. Jackson S.M., Ericsson J., Edwards P.A. Signaling molecule derived from cholesterol biosynthetic pathway. Subcell. Biochem. 1997, 28:1-21.
8. Dulak J., Jozkowiez A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to Anti-cancer therapy. Curr. Cancer Drug Targets 2005, 5:579-594.
9. Spampanato C., De M.S., Sarnataro M., Giordano E., Zanfardino M., Baiano S., Cartenì M., Morelli F. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int. J. Oncol. 2012, 40:935-941.
10. Cho S.J., Kim J.S., Kim J.M., Lee J.Y., Jung H.C., Song I.S. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int. J. Cancer 2008, 123:951-957.
11. Ghosh-Choudhury N., Mandal C.C., Ghosh-Choudhury N., Choudhury G. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell. Signal. 2010, 22:749-758.
12. Kochuparambil S.T., Al-Husein B., Goc A., Soliman S., Somanath P.R. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J. Pharmacol. Exp. Ther. 2011, 336:496-505.
13. Sassano A., Platanias L.C. Statins in tumor suppression. Cancer Lett. 2008, 260:11-19.
14. Campbell M.J., Esserman L.J., Zhou Y., Shoemaker M., Lobo M., Borman E., Baehner F., Kumar A.S., Adduci K., Marx C., Petricoin E.F., Liotta L.A., Winters M., Benz S. Breast cancer growth prevention by statins. Cancer Res. 2006, 66:8707-8714.
15. Thurnher M., Nussbaumer O., Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin. Cancer Res. 2012, 18:3524-3531.
16. Browning D.R., Martin R.M. Statins and risk of cancer: a systematic review and metanalysis. Int. J. Cancer 2006, 120:833-843.
17. Garwood E.R., Kumar A.S., Baehner F.L., Moore D.H., Au A., Hylton N., Flowers C.I., Garber J., Lesnikoski B.A., Hwang E.S., Olopade O., Port E.R., Campbell M., Esserman L.J. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res. Treat. 2010, 119:137-144.
18. Chae Y.K., Garwood E.R., Valsecchi M.E., Kim J., Bianchi A.L., Khemasuwan D., Desai A., Tester W. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 2011, 29:585-593.
19. Ahern T.P., Chae Y.K., Garwood E.R., Pedersen L., Tarp M., Cronin-Fenton D.P., Garne J.P., Silliman R.A., Sørensen H.T., Lash T.L. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J. Natl. Cancer. Inst. 2011, 103:1461-1468.
20. Jacobs E.J., Newton C.C., Thun M.J., Gapstur S.M. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 2011, 71:1763-1771.
21. Boudreau D.M., Yu O., Johnson J. Statin use and cancer risk: a comprehensive review. Exp. Opin. Drug Safety 2010, 9:603-621.
22. Thibault A., Samid D., Tompkins A.C., Figg W.D., Cooper M.R., Hohl R.J., Trepel J., Liang B., Patronas N., Venzon D.J., Reed E., Myers C.E. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 1996, 2:483-491.
23. Koyuturk M., Ersoz M., Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signaling through JNK. Cancer Lett. 2007, 250:220-228.
24. Sánchez C.A., Rodríguez E., Varela E., Zapata E., Páez A., Massó F.A., Montaño L.F., Lóopez-Marure R. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest. 2008, 26:698-707.
25. Kotamraju S., Williams C.L., Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res. 2007, 67:7386-7394.
26. Hwang K.E., Na K.S., Park D.S., Choi K.H., Kim B.R., Shim H., Jeong E.T., Kim H.R. Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest. New Drugs 2010, 29:945-952.
27. Ahn K.S., Sethi G., Aggarwal B.B. Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J. Immunol. 2007, 178:2507-2516.
28. Tiwary R., Yu W., Degraffenried L.A., Sanders B.G., Kline K. Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer. Breast Cancer Res. 2011, 13:R120.
29. Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int. J. Cancer 1994, 58:400-406.
30. Yu W., Israel K., Liao Q.Y., Aldaz C.M., Sanders B.G., Kline K. Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Res. 1999, 59:953-961.
31. Park S.K., Sanders B.G., Kline K. Tocotrienols induce apoptosis in breast cancer cell lines via an endoplasmic reticulum stress-dependent increase in extrinsic death receptor signaling. Breast Cancer Res. Treat. 2010, 124:361-375.
32. Tiwary R., Yu W., Li J., Park S.K., Sanders B.G., Kline K. Role of endoplasmic reticulum stress in alpha-TEA mediated TRAIL/DR5 death receptor dependent apoptosis. PLoS One 2010, 5:e11865.
33. Shetty S., Graham B.A., Brown J.G., Hu X., Vegh-Yarema N., Harding G., Paul J.T., Gibson S.B. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol. Cell Biol. 2005, 25:5404-5416.
34. Maldonado M.E., Bousserouel S., Gossé F., Lobstein A., Raul F. Implication of NF-κB and p53 in the expression of TRAIL-death receptors and apoptosis by apple procyanidins in human metastatic SW620 cells. Biomedica 2010, 30:577-586.
35. Zou W., Yue P., Khuri F.R., Sun S.Y. Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res. 2008, 68:7484-7492.
36. Ubeda M., Vallejo M., Habener J.F. CHOP enhancement of gene transcription by interactions with Jun/Fos AP-1 complex proteins. Mol. Cell Biol. 1999, 9:7589-7599.
37. Lei P., Abdelrahim M., Cho S.D., Liu S., Chintharlapalli S., Safe S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl) methanes inhibit colon cancer cell and tumor growth through activation of c-jun N-terminal kinase. Carcinogenesis 2008, 29:1139-1147.
38. Chen J.C., Wu M.L., Huang K.C., Lin W.W. HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression. Cardiovasc. Res. 2008, 80:138-150.
39. Saito A., Saito N., Mol W., Furukawa H., Tsutsumida A., Oyama A., Sekido M., Sasaki S., Yamamoto Y. Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008, 18:85-94.
40. Teramoto H., Crespo P., Coso O.A., Igishi T., Xu N., Gutkind J.S. The small GTP-binding protein rho activates c-Jun N-terminal kinases/stress-activated protein kinases in human kidney 293T cells. Evidence for a Pak-independent signaling pathway. J. Biol. Chem. 1996, 271:25731-25734.
41. Appierto V., Tiberio P., Villani M.G., Cavadini E., Formelli F. PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis 2009, 30:824-831.
42. Dasmahapatra G., Lembersky D., Rahmani M., Kramer L., Friedberg J., Fisher R.I., Dent P., Grant S. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol. Ther. 2009, 8:808-819.